Kidney drug may work through gut bacteria, study hints
NCT ID NCT05965440
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 50 non-diabetic people with chronic kidney disease to see if the drug dapagliflozin changes the types of bacteria in their gut. Researchers measured gut bacteria diversity and related waste products in the blood before and after 12 weeks of treatment. The goal was to understand how dapagliflozin might protect the kidneys beyond its known effects on blood sugar.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin
What this could lead to
If successful, this could help explain how dapagliflozin protects the kidneys, potentially leading to better treatments for chronic kidney disease.
What could go wrong
This is a small, observational study with only 50 participants and no control group. It looks at biological changes, not direct health outcomes, so results may not lead to clear conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nephrology department, Hôpital Lyon Sud, Hospices Civils de Lyon
Lyon, France